Investor Presentaiton
Serplulimab Entered into a New High-growth Stage of Commercialization with
Differentiated Advantage
6
MI
J
1.12B RMB
•
2023 sales revenue reached 1.12B RMB
In March 2023, Serplulimab achieved over RMB
100M monthly sales in China for the first time,
representing its commercialization stepping up
into new stage
By the end of 2023, Serplulimab has completed
tendering platform listing for all 31 provinces in
China, and established a commercial team of
~580 people with strong professional
communication skills and sales experience in
oncology
Clinical
Advantages
Serplulimab recommended by 9 Diagnosis and
Treatment Guidelines of CSCO in 2023
Including 2023 CSCO Diagnosis and Treatment
Guidelines for SCLC, NSCLC, EC, CRC and
Clinical Application Guideline for immune
checkpoint Inhibitor etc.
ASTRUM-004
•
•
In 2023 WCLC, oral presentation of the final
analysis results of total population for the first time
In 2023 ESMO Asia, the data from the Asian
subgroup were showcased in a poster session
In 2024, published online in Cancer Cell as its cover
feature
Differentiated
Indications
ES-SCLC (marketed):
ASTRUM-005 mOS: 15.8 vs 11.1 months
GC (Phase III):
Expected to be the world leading and the only
perioperative immune drug in China for GC
LS-SCLC (Phase III):
Expected to be the world's first PD-1 for the treatment of
LS-SCLC
mCRC (Phase II/III):
Phase II clinical data of 1L mCRC has been presented in
ASCO GI with the mPFS of 17.2 months; expected to
become the first approved PD-(L)1 for 1L mCRC
O 2024 Henlius.
2 HenliusView entire presentation